Clinical Trials Logo

Renal Transplant Failure clinical trials

View clinical trials related to Renal Transplant Failure.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05756036 Recruiting - Immunosuppression Clinical Trials

Torque Teno Virus: A Biomarker of Immunosuppression

Start date: February 15, 2022
Phase:
Study type: Observational

To seek an association between Torque Teno Virus DNA titres resulting from under or over-immunosuppression in a kidney allograft recipient, Graft rejection, both cell-mediated rejection and antibody-mediated rejection, donor-specific antibodies (DSA), the incidence of BK viraemia and BK nephropathy, CMV infection or diseases and PCP infection and the number of circulating NK, B and T lymphocyte subtypes.

NCT ID: NCT05243446 Recruiting - Clinical trials for Cardiovascular Complication

Cardiorenal Effecs of Losartan in Kidney Transplant Recipients

CELART
Start date: September 2015
Phase:
Study type: Observational

The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.

NCT ID: NCT04945785 Recruiting - Clinical trials for Renal Transplant Failure

" SAVE Study (Switch AdVagraf® to Envarsus®) for Fast Metabolizers Kidney Transplant Recipients"

SAVE
Start date: July 28, 2021
Phase:
Study type: Observational

The use of calcineurin inhibitors (CNIs) in kidney transplantation is the gold standard treatment to prevent episodes of rejection. Nevertheless, CNIs have side effects and are in particular nephrotoxic for the kidney transplant. Monitoring CNI dosages is fundamental for the clinician, in order to find the right balance between toxicity and prevention of rejection. Several recent studies suggest that a Radio Residual Concentration / Dosage (C0 / D) less than 1.05 (patients with rapid metabolizers) is associated with poor graft function (eGFR) and decreased kidney transplant survival. LCPT prolonged-release tacrolimus (Novel Once-Daily Extended-Release Tacrolimus. Prolonged-release tacrolimus: Envarsus®) is a marketed form of tacrolimus with interesting pharmacokinetic properties: daily intake, reduction of the absorption peak (Meltodose® technology ) and reduction of the total CNI dose by 30% to obtain an equivalent CO compared to other molecules on the market (Advagraf®, Prograf®). Thus, the use of LCPT in patients rapid metabolisers in relay of Advagraf® or Prograf® could make it possible to decrease renal toxicity while preserving rejection, by increasing the C0 / D ratio. The investigators propose a pilot study aiming to study a prospective cohort of rapid metabolisers patients put on Envarsus at one month of transplant compared to a historical cohort, in terms of C0 / D ratio, function and survival of the renal graft.